Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

BioAge Labs, Inc. (BIOA) vs Emergent Biosolutions Inc. (EBS)

BioAge Labs, Inc. and Emergent Biosolutions Inc. are both Drug Manufacturers Specialty & Generic companies. BioAge Labs, Inc. and Emergent Biosolutions Inc. are of similar size ($347.1M and $337.4M). Emergent Biosolutions Inc. has the higher net margin (−23.0% vs −912.3%) and the higher return on invested capital (−5.27% vs −118.3%). Across the 17 metrics below, Emergent Biosolutions Inc. leads on 9 and BioAge Labs, Inc. on 8.

Valuation

Metric BIOA EBS Drug Manufacturers Specialty & Generic median
P/E n/m n/m 20.14
P/S 30.53 0.45 2.25
P/B 0.84 1.03 1.90
Price to free cash flow n/m 4.07 16.54
EV/EBITDA 0.00 21.47 12.29
EV/Sales (0.04) 1.03 2.56
Earnings yield (33.76%) (50.66%) (2.99%)
Free cash flow yield (76.82%) 24.57% 0.00%

Profitability

Metric BIOA EBS Drug Manufacturers Specialty & Generic median
Gross margin 100.00% 55.87% 53.94%
Operating margin (1,026.28%) (8.57%) 0.00%
Net margin (912.25%) (22.96%) 0.00%
Free cash flow margin (2,345.11%) 11.18% 0.00%
Return on equity (28.21%) (40.29%) (0.40%)
Return on assets (26.27%) (13.95%) (3.32%)
Return on invested capital (118.25%) (5.27%) 0.00%

Growth

Metric BIOA EBS Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) — (9.56%) 10.01%
EPS growth (last fiscal year) 66.21% 125.83% —
Revenue growth, 5-year CAGR — (13.74%) 6.74%
Net income growth, 5-year CAGR — (29.64%) 0.00%

Health

Metric BIOA EBS Drug Manufacturers Specialty & Generic median
Debt to equity 0.00 1.70 0.05
Current ratio 17.19 5.42 2.31
Net debt to EBITDA 3.01 1.76 0.85

Dividend

Metric BIOA EBS Drug Manufacturers Specialty & Generic median
Dividend yield — 0.79% 1.70%
Payout ratio — 0.00 0.00

Size

Metric BIOA EBS Drug Manufacturers Specialty & Generic median
Market cap 337.35m 347.12m 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack